{"id":"W2910867209","doi":"10.1001/jama.2018.20588","title":"Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis","year":2019,"lang":"en","type":"article","venue":"JAMA","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":547,"is_retracted":false,"has_abstract":true,"ca_institutions":"Centre intégré de santé et de services sociaux de Chaudière-Appalaches; Hôpital Notre-Dame; Université de Montréal","funders":"National Health and Medical Research Council; Debreceni Egyetem; Dokuz Eylül Üniversitesi; Università degli Studi di Firenze; Multiple Sclerosis Society; York University; Wellcome Trust; American University of Beirut; Jewish General Hospital; National Institute for Health and Care Research; Teva Pharmaceutical Industries; Sanofi Genzyme; University of Melbourne; Medical Research Council; Biogen; NYU Langone Medical Center; NIHR Cambridge Biomedical Research Centre; Sanofi","keywords":"Medicine; Fingolimod; Glatiramer acetate; Natalizumab; Multiple sclerosis; Internal medicine; Hazard ratio; Alemtuzumab; Surgery; Disease; Confidence interval; Immunology","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001009068,0.0003273876,0.0003570857,0.0005335288,0.0002825231,0.0007311323,0.0004128717,0.0005302476,0.002337439],"category_scores_gemma":[0.005184024,0.0001835848,0.0007696655,0.0006015489,0.0003263409,0.0003117993,0.0003774421,0.00108278,0.000209356],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002788515,"about_ca_system_score_gemma":0.0002901265,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002143616,"about_ca_topic_score_gemma":0.002233563,"domain_scores_codex":[0.9990475,0.0002765557,0.0001180714,0.0002486537,0.0001999132,0.0001093171],"domain_scores_gemma":[0.9934472,0.001012533,0.004272877,0.0004400089,0.0003136354,0.0005137197],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.0004684961,0.00003237763,0.9969753,0.00001896114,0.0002446318,0.00007159915,0.00001328438,0.00007695333,0.0001480461,0.00002055986,0.0001018042,0.001827869],"study_design_scores_gemma":[0.00002890001,0.0001447661,0.9985184,0.00001379673,0.0001034004,0.0006249214,0.00001649222,0.0002682481,0.00008497184,0.00002923563,0.0001633132,0.000003491202],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9954284,0.002772866,0.000197806,0.0001520697,0.00002511653,0.00001721359,0.0003550716,0.00001473537,0.001036605],"genre_scores_gemma":[0.9992583,0.00021189,0.00007672048,0.00003792152,0.00002517174,0.000003209617,0.0002341697,0.000002241371,0.000150341],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002337439,"threshold_uncertainty_score":0.007819474,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0467230660719371,"score_gpt":0.3189398855219823,"score_spread":0.2722168194500452,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}